<DOC>
	<DOCNO>NCT01511003</DOCNO>
	<brief_summary>This study ass efficacy safety tacrolimus active rheumatoid arthritis patient show unsuccessful response exist DMARDs .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Tacrolimus Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response Existing Disease Modifying Antirheumatic Drugs ( DMARDs )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Subjects rheumatoid arthritis 6 month longer base American College Rheumatology ( ACR ) diagnostic criterion Subjects use 1 Disease Modifying Antirheumatic Drug ( DMARD ) include MTX ( methotrexate ) 6 month long Subjects ESR ( erythrocyte sedimentation rate ) ≥ 28mm/h CRP ( Creactive protein ) ≥ 1.0 mg/dL Subjects ≥ 3 swollen joint 66 joint assessed Subjects ≥ 6 tender joint 68 joint assessed Subjects BMD ( bone mineral densitometry ) ≤ 3.0 Pregnant nursing woman , subject plan become pregnant within 6 month whose screen test result show pregnancy rule Subjects previous experience tacrolimus ( exclude external preparation ) Subjects renal dysfunction serum creatinin &gt; 1.4 mg/dL screen Following subject hepatic dysfunction : viral infection , nonviral infection , hepatic cirrhosis , Serum Glutamic Oxaloacetic Transaminase / Serum Glutamic Pyruvic Transaminase ( SGOT/SGPT ) exceed twice upper limit normal screening Subjects pancreatitis , uncontrolled diabetes complication ( ) HbA1c &gt; 6.4 % screening Subjects complicate hyperkalemia serum potassium level &gt; 5.5 mEq/L screen Subjects history heart disease ( ischemic heart disease , arrhythmia require treatment , heart failure ) , etc complication Subjects complicate severe respiratory disease infection Subjects history malignant tumor complication ( ) ( However , subject consider risk recurrence malignant tumor untreated 5 year longer enter study . The subject succeed treatment basal cell squamous cell carcinoma skin also enter study . ) Subjects treat investigational product ( ) within 3 month screen Other subject consider ineligible study investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>calcineurin inhibitor</keyword>
	<keyword>Rheumatoid arthritis ( RA )</keyword>
</DOC>